VRTX Vertex Pharmaceuticals, Inc.
11,161
$402.50
$1.42
(0.35%)
| Watchers | 11,161 |
| 52-Wk Low | $320.01 |
| 52-Wk High | $448.40 |
| Market Cap | $103.97B |
| Volume | 1.46M |
| 52-Wk High | $448.40 |
| 52-Wk Low | $320.01 |
Vertex Reports First Quarter 2024 Financial ResultsBusiness Wire • about 6 hours ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. Vertex...
Share to Feed
:max_bytes(150000):strip_icc()/INV_DisneyHQ_GettyImages-1233255230-847cc0fe4d9744389de05723b3f8d11c.jpg)
Coming up: Federal Reserve officials speak, and Disney, Palantir, and Uber report earnings
Dania Maxwell / Los Angeles Times via Getty Images
Key TakeawaysEarnings reports scheduled from...
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO (ivacaftor) for the treatment of infants down to 1 month of...
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute...
:max_bytes(150000):strip_icc()/GettyImages-2102401647-7d1f2f62710e4fdf8ae272343c1b24bf.jpg)
Justin Sullivan / Staff / Getty Images
Key TakeawaysU.S. equities were mixed at midday Thursday, April 11, 2024 as the latest report on inflation showed wholesale prices rose less than expected...
:max_bytes(150000):strip_icc()/GettyImages-2010459008-079015b576724d41a3092e1cfb3678d6.jpg)
News of the day for April 11, 2024
Michael M. Santiago / Getty Images
U.S. stock futures are edging lower in premarket trading after tumbling Wednesday on the back of a hotter-than-forecast...
:max_bytes(150000):strip_icc()/VRTXChart-16089af1405e4288a0e607c8ad87c01a.GIF)
Deal Values Each Alpine Share at a 38% Premium to Wednesday's Closing Price
Source: TradingView.com
Key TakeawaysVertex shares slipped in extended trading Wednesday after the company...
Biotech company Vertex Pharmaceuticals said it is acquiring Alpine Immune Sciences in a cash deal valued at $4.9 billion, the company said in a statement on Wednesday. Read more...
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion...